362 related articles for article (PubMed ID: 29496721)
1. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.
El-Kattan AF; Varma MVS
Drug Metab Dispos; 2018 May; 46(5):729-739. PubMed ID: 29496721
[TBL] [Abstract][Full Text] [Related]
2. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
3. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
[TBL] [Abstract][Full Text] [Related]
4. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
Varma MV; Steyn SJ; Allerton C; El-Kattan AF
Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
[TBL] [Abstract][Full Text] [Related]
5. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
6. Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?
Alluri RV; Li R; Varma MVS
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):387-401. PubMed ID: 32228316
[No Abstract] [Full Text] [Related]
7. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
Momper JD; Tsunoda SM; Ma JD
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
[TBL] [Abstract][Full Text] [Related]
9. Plasma Protein Binding Refinement of the Extended Clearance Classification System: Subclasses for Predicting Hepatic Uptake or Renal Clearance for Classes 1B and 3B.
Khawaja Y; Haddad F; Hallak H
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):63-73. PubMed ID: 36441468
[TBL] [Abstract][Full Text] [Related]
10. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
11. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
12. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Shitara Y; Maeda K; Ikejiri K; Yoshida K; Horie T; Sugiyama Y
Biopharm Drug Dispos; 2013 Jan; 34(1):45-78. PubMed ID: 23115084
[TBL] [Abstract][Full Text] [Related]
14. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
15. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
16. Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.
Kimoto E; Mathialagan S; Tylaska L; Niosi M; Lin J; Carlo AA; Tess DA; Varma MVS
J Pharmacol Exp Ther; 2018 Nov; 367(2):322-334. PubMed ID: 30135178
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Veiga-Matos J; Remião F; Motales A
J Pharm Pharm Sci; 2020; 23():333-356. PubMed ID: 32997956
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
